Find where healthcare scale should create leverage, and why it does not.
Arvita Tripati helps healthcare operating partners and CEOs identify where growth is still scaling through labor, fragmentation, working capital and risk, and which interventions will change the economics.
Healthcare operator · Regulated product leader · Adviser to operating partners, CEOs and boards
Experience across FDA, NHS, VA, enterprise healthcare and complex therapies
AI activity is not the same as operating leverage.
Platforms accumulate pilots without an economic owner, point solutions without an operating model, automation layered onto fragmented workflows, and acquisitions that add scale without integration leverage.
A task becomes faster
An end-to-end care or revenue cycle improves
A team adopts a tool
Labor per episode or site declines
A model performs well
Capacity, margin, cash or quality improves
A pilot succeeds locally
The capability can be reused across sites
A vendor reports usage
Management can verify economic value
An answer is generated
A responsible decision is made faster
Where should scale improve growth,
clinical capacity, margin or cash,
and why has that leverage not appeared?
The decisions behind operating leverage
Where is value being lost?
Where demand, capacity or delivered care fails to become revenue, margin or cash.
What is causing the constraint?
Unnecessary work, clinical variation, fragmented systems, payer requirements or weak decision rights.
Which capability should the enterprise own?
What to standardize or govern centrally—and what must stay local.
What intervention is appropriate?
What to redesign, buy, integrate, automate, AI-enable, defer or stop.
What evidence will prove it worked?
The measures agreed before capital is committed.
How far the intervention should go
SCALED helps determine the simplest intervention capable of changing the economics. An organization may stop at any stage.
Simplify
Eliminate work before making it faster.
Codify
Common definitions, rules, evidence, ownership.
Aggregate
Share capability only where scale creates advantage.
Link
Connect systems, data and handoffs end to end.
Execute automatically
Automate stable, rules-based work.
Deploy AI selectively
Only where simpler methods are insufficient.
Before adding the next biologic
Six questions an infusion platform should answer before committing operating capacity and capital.
- DemandIs there enough addressable referral volume?
- EconomicsWhat drug, reimbursement, inventory and cash exposure will it create?
- AccessWill payers cover the therapy in the intended site of care?
- ReadinessWhat protocols, codes, systems, training and vendor changes are required?
- CapacityWhat chair, nursing, pharmacy and competency capacity will it consume?
- DurabilityCould a biosimilar, new indication or site-of-care policy alter the thesis?
Public evidence can reveal where the thesis deserves scrutiny. Internal operating and financial evidence determines whether the opportunity is real. Test the thesis against your portfolio →
A common economic question. Different operating constraints.
The economic question is consistent across healthcare services. The constrained resources and operating mechanisms are not.
Infusion
Therapy mix and site of care decide whether new referral volume adds contribution margin or only adds drug spend and cash exposure.
Constrained resource — chair, nursing and pharmacy hours
Read the infusion map →Behavioral health
Access, documentation load and utilization review decide whether census growth converts to billed, collected revenue.
Constrained resource — licensed clinician hours
Read the behavioral-health map →Selected research and writing
The same question examined across regulated healthcare: where scale should create leverage, and what it takes to make an investment hold up.
Built to Survive
Book · with Kimberly BloomstonWhy AI programs stall in review, and what it takes to get them bought, adopted and renewed.
About the book →Operating in Healthtech
NewsletterRegular notes on regulated product and operating decisions, including the calls that went the other way.
Subscribe →AI and Operating Leverage Diagnostic
For a company or portfolio company deciding where operating-model, technology and AI investment can create measurable value.
Prioritized value pools and economic mechanisms
Workflow and capability analysis
Build, buy, partner, integrate, defer or stop decisions
Pilot, measurement and governance plan
Regulated diagnostic scale-up.
Delivery 2.5 months → 4 weeks — operating-model and delivery redesign
Uptime 97% → 99.5% — enterprise reliability and execution
Operating-model advisory
Shared capabilities, decision rights, integration implications, vendor decisions and implementation oversight.
OngoingPortfolio and board advisory
Opportunity screening, management and vendor diligence, cross-portfolio capability strategy and capital allocation.
Retained or per decisionBest suited to leaders prepared to examine operating, financial and workflow evidence—not teams seeking generic AI training or outsourced software development.
Operating experience behind the method
The method comes from running regulated products and operations, not from observing them. Arvita has carried accountability for launches, capacity, quality and cost under real clinical and regulatory constraint.
Experience across regulated healthcare, complex therapies, diagnostics, digital health and enterprise operations, plus a Carnegie Mellon Chief Data and AI Officer certificate.
Full biography →From fragmented handoffs to a coordinated treatment journey
A patient-specific cell therapy must move from physician order through collection, manufacturing, transport and infusion without losing identity, timing or accountability at any handoff.
The value was not simply moving data between systems. It was maintaining identity fidelity, coordinating constrained capacity and making cross-organizational risk visible.
View the cell therapy operating journey →The operating challenge extended across organizations:
- Manual order entry and patient-identity risk
- Limited visibility across manufacturing and logistics
- Treatment scheduling dependent on product readiness
- Multiple clinical, operational and quality handoffs
- No single participant controlling the complete journey
An anonymized operating journey from therapy order through infusion.
“Arvita crushes challenging problems and creates order where there is uncertainty. I hired her, and she became an integral member of the leadership team. I hired her again to join me on the founding team at Korio.”
COO & co-founder, Korio
“I love Arvita’s discipline and the structure of her thinking. Her work was thorough, well-organized, and genuinely useful.”
University of Michigan
Where is growth adding enterprise value, and where is it only adding complexity?
A first conversation identifies whether the problem is specific, measurable and consequential enough to warrant a diagnostic.
Discuss a value-creation question →